drugset / Trial / NCT00355641
Long-Term Safety Of Ropinirole XR In Patients With Restless Legs Syndrome
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The primary objective of this study is to assess the safety and tolerability of ropinirole XR in the long-term treatment (up to 52 weeks)of adults with RLS.
Timeline
- Start
- 2005-10
- Primary completion
- 2007-10
- Completion
- 2007-10
Publications
- Background C Hill-Zabala, R Bogan, D Lee, M Lomax. A 52-week open-label study to assess the long-term tolerability of Ropinirole CR Extended Release Tablets in subjects with Restless Legs Syndrome (RLS). 12th International Congress of Parkinson's Disease and Movement Disorders, Chicago, IL, June 22-26, 2008 (abstract 1112).
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ropinirole | Small molecule | 0.5 mg | — |
| Subject | Ropinirole | Small molecule | 6 mg | — |